Epitranscriptomics represents an emerging frontier in biomedical research focused on the chemical and structural regulation of RNA. RNA molecules undergo numerous modifications and editing events—including N6-methyladenosine (m⁶A), pseudouridylation, 5-methylcytosine (m⁵C), and adenosine-to-inosine (A-to-I) RNA editing—that influence RNA structure, stability, translation, localization, degradation, and recognition by the immune system. Increasing evidence indicates that cancer cells can exploit these regulatory mechanisms to support tumor growth, adapt to cellular stress, and evade immune surveillance. This creates an opportunity to transform the cancer epitranscriptome from a biological phenomenon into a pharmacologically actionable therapeutic space.

At Dynoma Biosciences, we are exploring this opportunity through Pharmaceutical Epitranscriptomics for Cancer Immunotherapy (PETCI)—a research and development framework aimed at creating pharmaceutical tools that alter RNA modification, editing, structure, stability, and degradation to activate anti-cancer immune responses and promote cancer cell death.

A particularly promising aspect of this approach is the manipulation of RNA editing and modification pathways that normally prevent endogenous RNA from activating innate immunity. Cancer cells can depend on these mechanisms to conceal potentially immunogenic RNA species from intracellular nucleic-acid sensors. Pharmacologically disrupting selected RNA modifications or editing events could expose these endogenous RNAs to the cell's innate immune machinery, triggering inflammatory signaling, cellular stress, and programmed cell-death pathways. In this way, tumor RNA itself could potentially be transformed into an endogenous danger signal, helping make immunologically silent tumors more visible to the immune system.

Targeted RNA degradation provides another potential therapeutic dimension. Rather than inhibiting the protein produced by an oncogenic or immunosuppressive transcript, pharmaceutical tools could be designed to recognize selected RNA molecules and promote their degradation. This strategy could suppress oncogenic signaling, remove regulators of immune escape, or eliminate transcripts that allow cancer cells to tolerate innate immune activation. Importantly, targeting RNA may provide access to disease-driving pathways whose protein products have historically been difficult to drug.

The broader PETCI concept therefore extends beyond inhibiting individual RNA-modifying enzymes. We envision the cancer transcriptome as a pharmacologically programmable system in which RNA modification, editing, conformation, recognition, and degradation can potentially be manipulated to produce specific therapeutic outcomes.

RNA modification/editing → pharmaceutical intervention → altered RNA identity and fate → innate immune activation → cancer cell death → enhanced anti-tumor immunity

This approach could provide several important advantages for cancer therapy. It may expand the range of druggable cancer vulnerabilities beyond conventional proteins, simultaneously interfere with tumor survival and immune evasion, and create opportunities for combination with established immunotherapies such as immune-checkpoint blockade. Because RNA regulation is dynamic and context-dependent, it may also enable development of therapies directed toward specific molecular dependencies of individual tumor types.

At Dynoma Biosciences, our goal is to develop pharmaceutical tools capable of rewriting how cancer cells process, modify, and recognize their own RNA. By converting cancer-associated RNA states into therapeutic vulnerabilities and endogenous immune signals, PETCI represents a potential new direction for precision cancer immunotherapy—one in which RNA is not simply a messenger or biomarker, but a direct pharmaceutical target for activating anti-cancer immunity and cancer cell death.